OPERA at ten years: early ocrelizumab kept more patients below EDSS 6

Design

Two phase 3 randomised trials with open-label extension to 10 years

Population

1,656 adults with relapsing MS, EDSS 0–5.5

Primary outcome

48-week confirmed disability progression and EDSS milestones

Effect

CDP HR 0.76 (0.61 to 0.95); EDSS 6.0 HR 0.57 (0.40 to 0.82)

OPERA I and II randomised 1,656 adults with relapsing MS to ocrelizumab or interferon beta-1a for two years, after which everyone could take ocrelizumab in an open-label extension for up to eight more years. Eighty per cent entered the extension and 64% of those completed it.

Over ten years, those on ocrelizumab from the start had a lower hazard of 48-week confirmed disability progression (HR 0.76, 0.61 to 0.95) and of reaching EDSS 6.0, the point of needing a walking aid (HR 0.57, 0.40 to 0.82). The difference for EDSS 4.0 did not reach significance (HR 0.66, 0.43 to 1.03). Relapse rates in the continuous group fell from 0.139 in year 1 to 0.016 in year 10, and adverse event and serious infection rates did not rise over time.

The delayed group was not left untreated — interferon is an active drug — yet the two-year lag had not been made up by year ten. That strengthens the case for starting a high-efficacy therapy early rather than escalating after breakthrough. Long open-label extensions lose patients and lack blinding, but the comparison rests on the original randomisation.

• Consider high-efficacy therapy at diagnosis of active relapsing MS rather than escalating after relapses
• Discuss with patients that delayed effective treatment may cost disability that is not regained
• Monitor immunoglobulins and infection risk on long-term anti-CD20 treatment
• Plan pregnancy timing with women of childbearing potential before starting
• Weigh cost and access, which may decide which high-efficacy option is realistic

Why it matters

It is randomised long-term evidence against the escalation approach that many clinics still use by default.

Don't overread it

The extension was open-label and a third of patients did not complete it, so later estimates carry attrition bias.

The statistics, in plain English

A hazard ratio of 0.57 for EDSS 6.0 means early treatment cut the rate of reaching that milestone by 43% at any given time. The result for EDSS 4.0 crossed 1.0, so it is suggestive rather than established.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.